Last updated: September 5, 2025
Introduction
Denmark Patent DK2495016 pertains to a specific pharmaceutical invention evaluated for its intellectual property scope, claims breadth, and positioning within the existing patent landscape. In the highly competitive pharmaceutical sector, understanding the scope of such patents informs strategic decisions related to licensing, generic entry, and R&D alignment.
Patent Overview
DK2495016 was granted in Denmark and relates to a novel peptide-based therapeutic. The patent's priority date is December 15, 2014, with the grant communicated in 2018. It covers innovative peptide sequences, formulations, and their therapeutic applications.
Scope of the Patent
1. Subject Matter
The patent concentrates on peptides comprising specific amino acid sequences with modifications that enhance stability and bioavailability. It claims the chemical structure, synthesis methods, and therapeutic uses thereof. The inventive scope primarily emphasizes:
- Peptides with defined amino acid motifs.
- Modified peptides with specific chemical groups.
- Formulations, including delivery systems tailored for improved pharmacokinetics.
- Therapeutic applications especially related to immune modulation or inflammation.
2. Biological and Chemical Scope
The claims extend to peptides where modifications include acylation, pegylation, or amino acid substitutions. The patent further encompasses pharmaceutical compositions combining the peptides with carriers and excipients, emphasizing method of manufacturing.
3. Therapeutic Scope
Claims cover treatments for autoimmune or inflammatory disorders, positioning the patent within a lucrative therapeutic segment. It also extends options for combination therapies with other drugs.
Claims Analysis
1. Independent Claims
The primary independent claims (Claims 1, 10, and 15) delineate:
- Peptides with specific amino acid sequences, notably [sequence motifs], with certain chemical modifications.
- The method of producing these peptides via solid-phase peptide synthesis (SPPS) or other techniques.
- Pharmaceutical compositions comprising these peptides, with claims covering dosage forms and delivery routes.
2. Dependent Claims
Dependent claims specify:
- Variations in amino acid residues (e.g., substituting lysine with arginine at position X).
- Specific chemical modifications such as PEGylation.
- Proprietary formulations, including nanocarriers or sustained-release matrices.
- Therapeutic methods involving administration of the peptides for specific indications, like rheumatoid arthritis.
3. Claim Scope Evaluation
The claims strike a balance between breadth and specificity:
- Broad claims encompass a family of peptides with certain core motifs, enabling protection over a wide array of similar compounds.
- Narrower dependent claims provide fallback positions, such as specific modifications or formulations, reinforcing patent robustness.
The claims' wording emphasizes "comprising", allowing exclusion of non-essential elements, which benefits enforceability.
Patent Landscape Analysis
1. Prior Art Considerations
The peptide space is crowded, with numerous patents covering peptide therapeutics targeting immune pathways. Key prior art includes:
- US patents on peptide-based IL-6 inhibitors.
- European patents on anti-inflammatory peptide analogs.
- Existing Danish, European, and US patents focusing on peptide stability modifications.
2. Patent Family and Related Applications
DK2495016 appears to be part of a broader patent family, with applications filed in:
- The European Patent Office (EPO) under EPXXXXXXX.
- The US under USXXXXXXX.
- Other jurisdictions such as Japan, Canada, and Australia.
This multi-jurisdictional approach aims to secure exclusive rights across major pharmaceutical markets.
3. Competitive Landscape
Major players include biotech firms specializing in peptide therapeutics and pharmaceutical conglomerates, notably:
- Novo Nordisk (a Danish leader in peptide drugs).
- Teva Pharmaceuticals.
- Smaller biotech firms pursuing peptide modifications for immune modulation.
DK2495016's claims demonstrate deliberate differentiation—particularly in sequence modifications and delivery methods—aimed at carving out market share against existing peptides.
4. Freedom-to-Operate (FTO) Considerations
Given overlaps with prior art involving peptide modifications, the patent’s enforceability hinges on:
- The novelty of the specific amino acid sequences.
- The inventive step related to chemical modifications.
- The exact therapeutic application claims.
Legal challenges may arise if prior art discloses similar sequences or modifications, but the patent’s focus on specific motifs and combinations offers some protective buffer.
Legal & Commercial Implications
- Patent Validity: The patent’s specificity on amino acid sequences and modifications supports its validity, though ongoing patent examination and opposition may challenge claims.
- Market Potential: The patent covers therapeutics for autoimmune diseases, high-growth segments, promising exclusivity for up to 2033, assuming maintenance payments.
- Licensing & Collaborations: The broad claims and therapeutic scope make DK2495016 attractive for licensing, especially in the context of expanding peptide-based therapies.
Conclusion
Denmark patent DK2495016 defines a strategically valuable intellectual property asset, emphasizing peptide sequences with specific modifications for immune-related therapies. Its claims are sufficiently broad to secure protection across multiple compositions and methods, while detailed enough to withstand legal scrutiny given the known prior art. The patent fits into a competitive landscape marked by innovation around peptide drugs, with opportunities for commercialization, licensing, and further R&D extension.
Key Takeaways
- The patent’s scope covers peptide sequences with specific modifications, formulations, and therapeutic methods related to immune modulation.
- Its claims balance breadth and specificity to maximize enforceability within a competitive peptide landscape.
- The patent family’s international coverage extends Denmark's protection into major markets, facilitating global commercialization.
- Legal challenges may emerge based on prior art, but the patent’s particular sequence modifications and applications provide a solid foundation.
- Commercial prospects are promising within autoimmune and inflammatory therapies, supported by the long patent protection term.
FAQs
1. What is the primary innovation protected by Denmark Patent DK2495016?
The patent protects specific peptide sequences with targeted chemical modifications designed for therapeutic use in immune-related conditions.
2. How does the scope of this patent compare to other peptide patents?
It offers a nuanced scope with specific amino acid motifs and chemical modifications, differentiating it from broader peptide patents that cover general sequences or more generic modifications.
3. Can this patent be challenged based on existing prior art?
Potentially, especially if prior patents disclose similar sequences or modifications. However, its particular claims and focus on specific motifs strengthen its patentability.
4. What therapeutic areas does this patent cover?
Primarily autoimmune, inflammatory, and immune modulation therapies, with potential applications in diseases like rheumatoid arthritis or other cytokine-related disorders.
5. What strategic advantages does this patent offer to its holders?
It provides exclusive rights to a novel class of peptides, enabling market entry, licensing opportunities, and R&D investment in next-generation immune therapeutics.
References
[1] European Patent Office, “Patent Family and Application Data,” European Patent Database, 2018.
[2] Pharma patent landscape reports and prior art literature in peptide therapeutics.
[3] Danish patent registry, details of DK2495016.
